Torabizadeh Aalie, Vahidroodsari Fatemeh, Ghorbanpour Zakieh
Department of Obstetrics and Gynecology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Iran J Reprod Med. 2013 Oct;11(10):837-42.
Ovarian hyperstimulation syndrome (OHSS) is the most serious and potentially life-threatening iatrogenic complication associated with ovarian stimulation during Assisted Reproductive Technology (ART) protocols. OHSS typically is a result of ovarian expression of vascular endothelial growth factor (VEGF) which increases vascular permeability.
Comparison of albumin and cabergoline in the prevention of OHSS.
95 high risk infertile women for OHSS (more than 20 follicles in both ovaries at day of Human Chorionic Gonadotropin (HCG) injection) were randomly divided into two groups. First group including 48 women received 10 unit intravenous albumin at starting oocyte retrieval, and second group including 47 women received 0.5 mg/day dopamine agonist (Cabergolin) at day of HCG injection till 8 days. The dosage of human Menopausal Gonadotropin (HMG) used, total number of follicles developed, number of oocytes retrieved, serum E2 concentrations during the luteal phase, development of ascites, number of embryos generated, clinical pregnancy rate, results of the in vitro fertilization-embryo transfer (IVF-ET) cycles and incidence and severity of any OHSS were evaluated.
There was evidence of a statistically significant reduction in the incidence of OHSS in the cabergolin group (53.7%) versus albumin group (46.3%) (p=0.04). But there was no significant difference of a reduction in severe OHSS (p=0.62). There was no difference in clinical pregnancy rate too.
Administration of cabergolin can prevent incidence of OHSS and does not appear to effect on its severity.
IRCT138706281217N4.
卵巢过度刺激综合征（OHSS）是辅助生殖技术（ART）方案中与卵巢刺激相关的最严重且可能危及生命的医源性并发症。OHSS通常是卵巢表达血管内皮生长因子（VEGF）导致血管通透性增加的结果。
比较白蛋白和卡麦角林预防OHSS的效果。
95例OHSS高危不孕妇女（注射人绒毛膜促性腺激素（HCG）当天双侧卵巢卵泡均超过20个）被随机分为两组。第一组48例妇女在开始取卵时静脉注射10单位白蛋白，第二组47例妇女在注射HCG当天开始每天服用0.5毫克多巴胺激动剂（卡麦角林），持续8天。评估使用的人绝经期促性腺激素（HMG）剂量、发育的卵泡总数、取出的卵母细胞数、黄体期血清E2浓度、腹水形成情况、产生的胚胎数、临床妊娠率、体外受精-胚胎移植（IVF-ET）周期结果以及任何OHSS的发生率和严重程度。
有证据表明卡麦角林组OHSS发生率（53.7%）与白蛋白组（46.3%）相比有统计学显著降低（p = 0.04）。但重度OHSS发生率降低无显著差异（p = 0.62）。临床妊娠率也无差异。
服用卡麦角林可预防OHSS的发生，且似乎不影响其严重程度。
IRCT138706281217N4
